NRXS

Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.

Wall Street analysts forecast NRXS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRXS is  USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Neuraxis Inc revenue for the last quarter amounts to 811.41K USD, increased 21.72 % YoY.

Neuraxis Inc. EPS for the last quarter amounts to -0.24 USD, decreased -4.00 % YoY.

Neuraxis Inc (NRXS) has 21 emplpoyees as of December 16 2025.

Today NRXS has the market capitalization of 28.23M USD.